Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Analysts have trimmed their fair value price target for Grifols from €15.08 to €14.65, while broader published price targets now cluster in the €10 to €11 range. This reset lines up with a more cautious tone in recent research, where questions around revenue visibility and slower albumin and alpha-1 volumes have led to reduced conviction on upside. As you read on, you will see how this evolving narrative might shape the way you track the stock from here.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Morgan Stanley, even after moving to Equal Weight, still assigns an €11 price target. This sits toward the upper end of the current published range and signals some remaining confidence in the stock's valuation support.
-
Both Deutsche Bank and Morgan Stanley continue to cover Grifols closely. This gives you ongoing external reference points on execution around albumin and alpha-1, rather than a complete pullback in coverage.
🐻 Bearish Takeaways
-
Morgan Stanley cut its rating to Equal Weight from Overweight and scaled its price target down to €11 from €14. The firm explicitly pointed to uncertainties around revenue growth given slower albumin and alpha-1 trends.
-
Deutsche Bank lowered its price target to €10 from €11 while maintaining a Hold stance. This reinforces the recent pattern of trimmed expectations and more cautious views on upside potential.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for Grifols. See which could impact your investment.
What's in the News
-
Health Canada has imposed new conditions on Grifols, which investors may read as a sign of increased regulatory focus on the business, according to CBC News.
-
Grifols' Board of Directors is evaluating a potential US IPO of a portion of the shares of its subsidiary that is the parent of its US Biopharma business as part of its self sufficiency programs for Biopharma.
-
The company states that any potential US IPO would depend on regulatory and legal requirements, internal approvals and market conditions, and that there is no assurance an IPO will be undertaken or completed.
-
Grifols has indicated its stock would continue to trade in Spain through the mercado continuo regardless of whether a US IPO of the Biopharma subsidiary proceeds.
How This Changes the Fair Value For Grifols
-
Fair value trimmed from €15.08 to €14.65, a reduction of about 3%.
-
Revenue growth adjusted from 5.63% to 5.93%, a shift of roughly 0.3 percentage points.
-
Profit margin kept essentially steady at about 10.14% versus 10.11%.
-
Future P/E revised from 15.70x to 15.13x, reflecting a slight compression in the multiple used.
-
Discount rate moved from 11.24% to 10.74%, a decline of around 0.5 percentage points.
Never Miss an Update: Follow The Narrative
Narratives connect a company's real world story to a set of financial forecasts and a fair value estimate, so you can see how news and fundamentals line up. They refresh as new information comes in, helping you keep your investment case up to date.
Head over to the Simply Wall St Community and follow the Narrative on Grifols to stay up to date on:
-
How expanding plasma therapies, new products like fibrinogen, and entry into markets such as China and Canada feed into the growth story.
-
What investments in plasma collection efficiency, cost control, and deleveraging could mean for cash flow, margins, and balance sheet strength.
-
Key risks around pricing pressure in China, dependence on plasma collection centers, rising competition from alternative therapies, and the impact of high debt levels.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GRF.MC .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
